SEC Form 4 · accession 0001209191-18-019694
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Rutherford
Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $7.29 | Mar 12, 2018 | A | 15,000 | A | — | Mar 12, 2028 | Common Stock | 15,000 | 15,000 | D |
| Stock option (right to buy)F2 | $7.29 | Mar 12, 2018 | A | 24,691 | A | — | Mar 12, 2028 | Common Stock | 24,691 | 24,691 | D |
Explanation of responses
- F1Mr. Rutherford acquired a vested interest in one hundred percent (100%) of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services.
- F2The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services.
Remarks
The options were granted subject to stockholder approval and will be forfeited if stockholder approval is not obtained within twelve months of the date of grant.